SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine

Summary

The purpose of this study is to evaluate the safety and efficacy of mRNA COVID-19 vaccines in: • People with prior COVID-19 (SARS-CoV-2 infection) who were in the ACTIV-2/A5401 study. And • People who have never had COVID-19 (SARS-CoV-2 infection).

Timeline

Start

2021-07-09

Primary completion

2022-02-28

Completion

2023-01-10

Publications

• Smith D, Weir IR, Ramirez S, Coelho CH, Manne-Goehler J, Aziz M, Benson CA, Wu X, Hyer R, Dhillon PK, Faraji F, Bloom N, Myers A, Ramezani-Rad P, Lopez PG, Parikh UM, Heaps AL, Javan AC, Bender Ignacio RA, Li JZ, Greninger AL, Daar ES, Wohl DA, Crotty S, Sieg SF, Chew KW. Impact of COVID-19 Monoclonal Antibody Therapy on Subsequent Vaccine-elicited SARS-CoV-2 Immune Responses. J Infect Dis. 2026 Feb 17:jiag091. doi: 10.1093/infdis/jiag091. Online ahead of print.

Drugs

Indications